Results 21 to 30 of about 117,898 (292)

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V., Antolino A., Di Raimondo F., Forte S., Impera S., Malato A., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Musso M., Pennisi M. S., Porretto F., Russo S., Siragusa S., Spitaleri A., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +23 more
core   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Haematologica, 2016
The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of ≥12 months were analyzed.
Sung-Eun Lee, Soo Young Choi, Hye-Young Song, Soo-Hyun Kim, Mi-Yeon Choi, Joon Seong Park, Hyeoung-Joon Kim, Sung-Hyun Kim, Dae Young Zang, Sukjoong Oh, Hawk Kim, Young Rok Do, Jae-Yong Kwak, Jeong-A Kim, Dae-Young Kim, Yeung-Chul Mun, Won Sik Lee, Myung Hee Chang, Jinny Park, Ji Hyun Kwon, Dong-Wook Kim   +20 more
doaj   +1 more source

Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. [PDF]

, 2019
Dysregulation of the seven-transmembrane (7TM) receptor Smoothened (SMO) and other components of the Hedgehog (Hh) signaling pathway contributes to the development of cancers including basal cell carcinoma (BCC) and medulloblastoma (MB).
Abagyan, Ruben, Chahal, Kirti Kandhwal, Chen, Clark C, Durden, Donald L, Kufareva, Irina, Li, Jie, Parle, Milind, Wechsler-Reya, Robert J   +7 more
core   +1 more source

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]

, 2018
The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core   +1 more source

Imatinib-Induced Psoriasis

Turkish Journal of Hematology, 2013
Imatinib is a signal transduction regulator that selectively inhibits the tyrosine kinase family, including bcr-abl and c-kit, and the platelet-derived growth factor (PDGF) receptor. It is currently the fi rst-line therapy for newly diagnosed chronic myeloid leukemia (CML) patients [1].
Atalay, Figen, Kizilkilic, Ebru, Ada, R. Simin   +2 more
openaire   +4 more sources

Imatinib

Japanese Journal of Clinical Immunology, 2009
The progress in molecular targeting therapy includes two tides, namely, small molecule compounds and large molecule biological agents. Although the latter prevails in the field of clinical immunology, the former attracts more and more attention in these few years.
openaire   +4 more sources

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib

Gastroenterology Research and Practice, 2014
Purpose. This retrospective, nonrandomized study investigated the effect of imatinib rechallenge plus best supportive care (BSC) on overall survival after imatinib and sunitinib treatment for patients with locally advanced or metastatic gastrointestinal ...
Akira Sawaki, Tatsuo Kanda, Yoshito Komatsu, Toshirou Nishida   +3 more
doaj   +1 more source

Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells. [PDF]

, 2014
To enable new blood vessel growth, endothelial cells (ECs) express neuropilin 1 (NRP1), and NRP1 associates with the receptor tyrosine kinase VEGFR2 after binding the vascular endothelial growth factor A (VEGF) to enhance arteriogenesis.
Alessandro Fantin, Anastasia Lampropoulou, Anissa Chikh, Anselmi, Ballmer-Hofer, Baruzzi, Birukova, Buchdunger, Campochiaro, Carmeliet, Casanovas, Chen, Chen, Chislock, Cho, Choi, Christiana Ruhrberg, Clark, Claudio Raimondi, Colicelli, Connor, Cui, Cujec, Dejana, Druker, Fantin, Fantin, Fantin, Fantin, Foxton, Fukasawa, Gerhardt, Gerhardt, Herzog, Kawamura, Kawasaki, Kim, Kitsukawa, Koch, Lanahan, Lanahan, Laura Denti, Lewis, Lewis, Mamluk, Murga, Nishijima, Pan, Pan, Parsons, Pasapera, Phng, Raimondi, Ren, Robinson, Roig, Rosenfeld, Ruhrberg, Ruhrberg, Saint-Geniez, Salikhova, Shimizu, Shojaei, Smith, Soker, Sottile, Stenzel, Tvorogov, Uemura, Valdembri, Wang, Welti, Yaqoob, Zaidel-Bar, Zhuang   +74 more
core   +4 more sources

Effects of imatinib on vascular insulin sensitivity and free fatty acid transport in early weight gain.

PLoS ONE, 2021
BackgroundVascular endothelial dysfunction is an essential part of the pathophysiology of type 2 diabetes and its complications. In type 2 diabetes, endothelial dysfunction is characterized by reduced insulin signaling and increased transendothelial ...
Camiel V J Box, Amandeep K Sandhu, Alexander H Turaihi, Pan Xiaoké, Geesje Dallinga-Thie, Jurjan Aman, Etto C Eringa   +6 more
doaj   +1 more source